Talc Pleurodesis

Key Point

Pleurodesis should only be performed under the guidance of the Chest Physicians or Oncologists.

This is a controlled document. If you are using a printed copy, check it against the guidelines site to ensure you are using the latest edition.

Print copies must be destroyed after use.

Abbreviations

ARDSAcute Respiratory Distress Syndrome
NSAIDSNon steroidal anti-inflammatory drugs

Verbal consent to cover:

  1. Failure of pleurodesis (30%).

  2. Pain

  3. ARDS (rare, <1%)

  4. Pleural infection

Indications

  • In management of recurrent malignant pleural effusion

  • Prevention of recurrent of secondary spontaneous pneumothorax in adults (e.g., patients with severe chronic obstructive pulmonary disease who significantly decompensated in the presence of a pneumothorax, even during/after the first episode).

Procedure

N.B. Using sterile technique

Pre-procedure preparation

1 x assistant

Materials Required

4g vial of sterile talc

20mls 1% Lidocaine

100ml bag of 0.9% normal saline

20ml syringe x 2

50ml luer lock syringe

Sterile pack

Green needle x 3

Sterile gloves x 2

Anaesthetise the pleura

  • Flush the drain with a small amount of the saline flush

  • Inject the 20mls of 1% Lidocaine into the drain and

  • close the 3-way tap

  • Leave for 5-10 minutes

Pleurodesis

Prepare the talc slurry

  • Draw 50mls 0.9% normal saline into the 50ml syringe

  • Upside down, remove the needle from the end of the syringe and almost withdraw the plunger

  • Place a finger over the end of the 50ml syringe, turn downward and pull the plunger out of the top of the syringe (as illustrated)

  • Ask your assistant to pour the talc into the top of the 50ml syringe

  • Place the plunger back into the syringe, turn it upside down and shake the syringe to mix its contents.

  • Inject the mixture into the drain

  • Flush the drain with 20 ml of normal saline

  • Close the 3-way tap for 1 hour

imogens hands

Post Procedure

  • After 1 hour, open the drain to the underwater seal bottle.

  • The chest drain can be removed when output is less than 150mls/day (excluding flushes) or 24-48 hours post procedure.

  • Make sure that prophylactic Low Molecular Weight Heparin is prescribed (unless contraindicated).

  • Prescribe analgesia (Paracetamol, Codeine - not NSAIDs).

  • Prescribe 10mls Normal Saline drain flushes qds.

Observations: ask the nursing staff to perform ½ hourly observations for 2 hours and then 6 hourly, and inform a doctor if the patient becomes unwell.

Other Considerations

Concomitant medications- systemic corticosteroids may decrease the success of talc pleurodesis due to their anti-inflammatory properties, as can (potentially) NSAIDs.

Reference

Roberts, M.E. et al. (2023) 'British Thoracic Society Guideline for pleural disease', Thorax, 78(Suppl 3), pp. s1-s42. Available at: https://doi.org/10.1136/thorax-2022-219784

Full version control record

Version:1.0
Guidelines Lead(s):Dr S Power, Consultant Respiratory Physician, Pleural Lead
Contributor(s):Dr N Stolagiewicz, Consultant Chest Physician
Dr Su Latt Phyu, Respiratory Registrar
Lead Director / Chief of Service:Dr Chris Orchard, Consultant Respiratory Physician, CoS for Medicine
Library check completed:22/05/2024
Ratified at:Respiratory Cross Site Clinical Governance Team, 11 October 2024
Date Issued:22 November 2024
Review Date:October 2027
Pharmaceutical dosing advice and formulary compliance checked by:Ijeoma Udeagbala-Okumah, Lead Pharmacist – Respiratory Medicine, 23/07/2024
Keywords:Talc pleurodesis, pleural disease, pleural effusion, pneumothorax

This guideline has been registered with the Trust. However, clinical guidelines are guidelines only. The interpretation and application of clinical guidelines will remain the responsibility of the individual clinician. If in doubt, contact a senior colleague or expert. Caution is advised when using guidelines after the review date.

This guideline is for use in Frimley Health NHS Foundation Trust hospitals only. Any use outside this location will not be supported by the Trust and will be at the risk of the individual using it.

Version History

VersionDateGuideline Lead(s)StatusComment
1.0 (WPH)Nov 2010Dr S Menzies, Consultant Respiratory PhysicianFinal
2.0 (WPH)June 2013Dr S Menzies, Consultant Respiratory PhysicianFinal
3.0 (WPH)Feb 2016Dr S Menzies, Consultant Respiratory PhysicianFinal
1.0 (FH)March 2024Dr S PowerFinalFull review, now trust-wide.

Related Documents

None